A compendium of critical appraisals in Intensive Care Medicine research and related specialties
In patients who have recently taken factor Xa inhibitors with an intracerebral haemorrhage (ICH) did the administration of Andexanet result in better haemostatic efficacy compared to standard care?
Continue reading »
In patients with gastrointestinal (GI) bleeding does high dose tranexamic acid (TXA) when compared to a placebo reduce mortality from GI bleeding?
Continue reading »
Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH – 3): a randomised, placebo-controlled trial The CRASH-3 trial collaborators. The Lancet, 2019; doi.org/10.1016/S1040-6736(19)32233-0 Clinical Question In patients with traumatic brain injury (TBI), does the administration of tranexamic acid (TXA) under 3 hours from injury, compared with placebo, reduce […]
Continue reading »
In patients with atrial fibrillation (AF) on direct oral anticoagulant (DOAC) medications, does a standard approach to therapy interruption and resumption in the perioperative period result in an acceptable risk for bleeding and thromboembolic events?
Continue reading »
In patients with anterior circulation strokes undergoing endovascular thrombectomy, is IV thrombolysis within 4.5 hours of stroke onset with tenecteplase, non-inferior to alteplase, at establishing reperfusion?
Continue reading »
In patients with acute coronary syndromes without ST elevation, does clopidogrel + aspirin, compared with aspirin alone, reduce a composite outcome of death from cardiovascular causes, acute myocardial infarction and stroke?
Continue reading »
In critically ill patients requiring continuous renal replacement therapy (CRRT), does regional anticoagulation with citrate prolong circuit life compared to heparin and protamine?
Continue reading »
In healthy adults taking either apixaban (ANNEXA-A) or rivaroxaban (ANNEXA-R) does andexanet alfa compared to placebo normalise anticoagulation?
Continue reading »
In patients taking dabigatran, who present with serious bleeding or require urgent surgery/intervention is idarucizumab safe and efficacious for the reversal of anticoagulation?
Continue reading »
In elective surgical patients with atrial fibrillation who are suspending their normal warfarin peri-operatively, does no bridging anticoagulation compared to bridging anticoagulation with dalteparin increase the incidence of thromboembolism or reduce the incidence of major bleeding?
Continue reading »